Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [843]

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast...

Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )

(RVd) ± , stem cell transplantation and R maintenance shows significance for...

Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA )

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides...

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

Everolimus after surgery can improve outcomes in those with high-risk kidney...

Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer ( Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

The adverse events atlas, towards a strategy to predict synergistic adverse...

Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands

The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies ( Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands )

Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid...

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1...

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

FAP-targeted PET imaging in cancer patients

Prof Jérémie Calais - UCLA, Los Angeles, USA

FAP-targeted PET imaging in cancer patients ( Prof Jérémie Calais - UCLA, Los Angeles, USA )

Immune gene signatures for predicting response to neoadjuvant...

Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda...

Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC ( Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain )

More from ecancer